Revive Therapeutics

Compass Pathways’ Psilocybin Clears First Phase 3 HurdleJune 23, 2025
This morning, Compass Pathways shared the first cut of Phase 3 data for a classical psychedelic, reporting a statistically significant MADRS difference vs. placebo and a reassuring safety profile in its trial of COMP360 psilocybin for treatment-resistant depression. Here, we provide our quick-take analysis and speak with company execs about the news.
Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind ProgramJune 18, 2025
Australia’s largest private health insurer, Medibank, has launched a first-of-its-kind funding program for MDMA-assisted therapy for PTSD as part of its ‘innovative psychotherapy program’. That makes it the first payor in the country to back psychedelic-assisted psychotherapy.
Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are FragileJune 13, 2025
EU Member States as Laboratories of Democracy? Conference Discusses Czechia’s Psychedelic Future at Prague Castle • At ‘the Davos of Mental Health’, Investors Eye Psychedelics’ Next Chapter • Psychedelic Alpha at Psychedelic Science 2025 • High-Dose LSD Shows Potential in Depression Trial, But Findings Are Fragile • and more…
May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-DMT Patent LandscapeJune 12, 2025
Explore or interactive database of psychedelic patent activity in May 2025 via our Pα+ interface. We also cover a handful of related headlines: from Gilgamesh Pharmaceuticals’ IP around its lead candidate, GM-2505, through to new published applications from Reconnect Labs that claim compositions of 5-MeO-DMT.
Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer Look at ‘atai Beckley’; Q1’25 Psychedelic Lobbying Update; Catching Up with the Class of Bulletin #100June 6, 2025
The Class of Bulletin #100: Where Are They Now? • Can Czechia Deliver on Psilocybin Access and Provide a Model for the Continent? • A Closer Look at atai’s Potential Acquisition of Beckley Psytech • Q1’25 Psychedelic Lobbying Update • Holy Trips and Hot Takes: Religious Leaders Study Finally Published • and much, much more…

Revive Therapeutics

Latest News

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. Expands Life Offering to Quebec

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

Join our Newsletter

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights